Boothbay Fund Management’s Beam Therapeutics BEAM Stock Holding History
Bought
Maintained
Sold
Other funds holding BEAM
FCM
AIM
AVM
NAMA
Boothbay Fund Management's BEAM Position: Q2 2026 in Review
Boothbay Fund Management opened a new position in Beam Therapeutics (BEAM) in Q2 2026: 15,027 shares worth $516K. The stake represents 0.01% of the portfolio and ranks #1476 among its holdings. This is a return to the name: Boothbay Fund Management previously reported a position in BEAM as recently as Q4 2025.
Boothbay Fund Management first reported a position in BEAM in Q3 2025 and has held it in 3 quarters since. The position peaked at $1.68M in Q4 2025. 277 funds tracked by Wall St. Rank hold BEAM as of Q2 2026.
- Boothbay Fund Management held 15,027 shares of Beam Therapeutics worth $516K as of Q2 2026.
- Beam Therapeutics was a new Boothbay Fund Management position in Q2 2026.
- Beam Therapeutics made up 0.01% of Boothbay Fund Management's portfolio in Q2 2026, its #1476 holding.
- Boothbay Fund Management first reported a position in Beam Therapeutics in Q3 2025 and has held it in 3 quarters since.
- Boothbay Fund Management's Beam Therapeutics position peaked at $1.68M in Q4 2025.
- 277 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2026.
Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.